Abstract:Alcohol exposure is a major reason of morbidity and mortality all over the world, with much of detrimental consequences attributing to alcoholic liver disease (ALD). With the continued ethanol consumption, alcoholic fatty liver disease (AFLD, the earliest and reversible form of ALD) can further develop to more serious forms of alcoholic liver damage, including alcoholic steatohepatitis, fibrosis/cirrhosis, and even eventually progress to hepatocellular carcinoma and liver failure. Furthermore, cell trauma, inflammation, oxidative stress, regeneration, and bacterial translocation are crucial promoters of ethanol-mediated liver lesions. AFLD is characterized by excessive fat deposition in liver induced by excessive drinking, which is related closely to the raised synthesis of fatty acids and triglyceride, reduction of mitochondrial fatty acid β-oxidation, and the aggregation of very-low-density lipoprotein (VLDL). Although little is known about the cellular and molecular mechanisms of AFLD, it seems to be correlated to diverse signal channels. Massive studies have suggested that liver steatosis is closely associated with the inhibition of silent information regulator 1 (SIRT1) and the augment of lipin1 β/α ratio mediated by ethanol. Recently, serine/arginine-rich splicing factor 10 (SFRS10), a specific molecule functioning in alternative splicing of lipin 1 (LPIN1) pre-mRNAs, has emerged as the central connection between SIRT1 and lipin1 signaling. It seems a new signaling axis, SIRT1–SFRS10–LPIN1 axis, acting in the pathogenesis of AFLD exists. This article aims to further explore the interactions among the above three molecules and their influences on the development of AFLD. Impact statement ALD is a major health burden in industrialized countries as well as China. AFLD, the earliest and reversible form of ALD, can progress to hepatitis, fibrosis/cirrhosis, even hepatoma. While the mechanisms, by which ethanol consumption leads to AFLD, are complicated and multiple, and remain incompletely understood. SIRT1, SFRS10, and LIPIN1 had been separately reported to participate in lipid metabolism and the pathogenesis of AFLD. Noteworthy, we found the connection among them via searching articles in PubMed and we had elaborated the connection in detail in this minireview. It seems a new signaling axis, SIRT1–SFRS10–LIPIN1 axis, acting in the pathogenesis of AFLD exists. Further study aimed at SIRT1–SFRS10–LIPIN1 signaling system will possibly offer a more effective therapeutic target for AFLD.

Targeting hepatic serine-arginine protein kinase 2 ameliorates alcohol-associated liver disease by alternative splicing control of lipogenesis

FXR and TGR5 Agonists Ameliorate Liver Injury, Steatosis, and Inflammation After Binge or Prolonged Alcohol Feeding in Mice

Pharmacological inhibition of the Src homology phosphatase 2 confers partial protection in a mouse model of alcohol-associated liver disease

Stress-Responsive Gene FK506-Binding Protein 51 Mediates Alcohol-Induced Liver Injury Through the Hippo Pathway and Chemokine (C-X-C Motif) Ligand 1 Signaling

Epithelial Splicing Regulatory Protein 2-Mediated Alternative Splicing Reprograms Hepatocytes in Severe Alcoholic Hepatitis

Ablation of secreted phosphoprotein‐1 in hepatocytes increases fatty acid oxidation and ameliorates alcohol‐associated liver disease

Genetic ablation of fas-activated serine/threonine kinase ameliorates alcoholic liver disease through modulating HuR-SIRT1 mRNA complex stability

Gut-restricted apical sodium-dependent bile acid transporter inhibitor attenuates alcohol-induced liver steatosis and injury in mice

Roles of silent information regulator 1–serine/arginine-rich splicing factor 10–lipin 1 axis in the pathogenesis of alcohol fatty liver disease

Inhibition of Sphingosine‐1‐Phosphate‐Induced Th17 Cells Ameliorates Alcohol‐Associated Steatohepatitis in Mice

Fibroblast Growth Factor 21 Deficiency Exacerbates Chronic Alcohol-Induced Hepatic Steatosis and Injury

LncRNA H19 promoted alcohol-associated liver disease through dysregulation of alternative splicing and methionine metabolism

FGF21 deficiency exacerbates chronic alcohol induced fatty liver disease via a p38MAPK and PGC-1α mediated pathway (653.13)

DEP Domain–containing Mtor–interacting Protein Suppresses Lipogenesis and Ameliorates Hepatic Steatosis and Acute‐on‐chronic Liver Injury in Alcoholic Liver Disease

Phospholipase D2 Drives Cellular Lipotoxicity and Tissue Inflammation in Alcohol-Associated Liver Disease

Nuclear factor Y participates in alcoholic liver disease by activating SREBP1 expression in mice

Ubiquitin-specific protease 22 ameliorates chronic alcohol-associated liver disease by regulating BRD4

Hepatic Proteomic Changes Associated with Liver Injury Caused by Alcohol Consumption in Fpr2-/ - Mice

Activation of Farnesoid X Receptor Attenuates Hepatic Injury in a Murine Model of Alcoholic Liver Disease.

Modulation of the intestinal bile acid/farnesoid X receptor/fibroblast growth factor 15 axis improves alcoholic liver disease in mice

ASPP2 Deficiency Attenuates Lipid Accumulation Through the PPARγ Pathway in Alcoholic Liver Injury